A new analysis of Medicare data has found that prostate cancer patients who use testosterone replacement therapy live just as long as those who don’t and do not have greater need for androgen deprivation therapy.
Researchers from the University of Missouri recently published study results indicating testosterone may play an integral role within colon cancer tumor formation.
There had been a “remarkable convergence of many disciplines” when weighing the health risks and effectiveness of testosterone replacement therapy (TRT), according to an article published in JAMA.
Yet another large study has found that testosterone replacement therapy is more likely to reduce than increase the risk of major adverse cardiac events.
A white paper from the American Urological Association warns physicians about significant problems with existing testosterone evaluation practices and outlines strategies for ensuring the right patients receive the right replacement therapy.
According to the Pharmacovigilance Risk Assessment Committee, there is no consistent evidence showing that the use of testosterone replacement therapy increases the risk of heart problems in men with low testosterone.